These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 15511259)

  • 1. Gatifloxacin induced torsades de pointes.
    Fteha A; Fteha E; Haq S; Kozer L; Saul B; Kassotis J
    Pacing Clin Electrophysiol; 2004 Oct; 27(10):1449-50. PubMed ID: 15511259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors.
    Amankwa K; Krishnan SC; Tisdale JE
    Clin Pharmacol Ther; 2004 Mar; 75(3):242-7. PubMed ID: 15001976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors.
    Bertino JS; Owens RC; Carnes TD; Iannini PB
    Clin Infect Dis; 2002 Mar; 34(6):861-3. PubMed ID: 11830802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Torsade de pointes probably induced by sparfloxain.
    Ahluwalia G
    J Assoc Physicians India; 2003 Aug; 51():835; author reply 835. PubMed ID: 14651157
    [No Abstract]   [Full Text] [Related]  

  • 5. QT interval prolongation and torsades de pointes due to erythromycin lactobionate.
    Oberg KC; Bauman JL
    Pharmacotherapy; 1995; 15(6):687-92. PubMed ID: 8602374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moxifloxacin and torsade de pointes.
    Dale KM; Lertsburapa K; Kluger J; White CM
    Ann Pharmacother; 2007 Feb; 41(2):336-40. PubMed ID: 17284508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of sensitivity of surrogate markers of drug-induced torsades de pointes in canine hearts.
    Chiba K; Sugiyama A; Takasuna K; Hashimoto K
    Eur J Pharmacol; 2004 Oct; 502(1-2):117-22. PubMed ID: 15464097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
    Arbel Y; Swartzon M; Justo D
    Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ciprofloxacin-induced torsades de pointes in a methadone-dependent patient.
    Nair MK; Patel K; Starer PJ
    Addiction; 2008 Dec; 103(12):2062-4. PubMed ID: 19469750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ['Cardiac ballet' with and without amiodarone].
    Balestra B; Hess T
    Schweiz Med Wochenschr; 1993 Jan; 123(1-2):20-5. PubMed ID: 8421775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Torsades de pointes ventricular tachycardia induced by intravenous amiodarone].
    Makai A; Rudas L; Liszkai G; Fazekas T
    Orv Hetil; 2003 Feb; 144(5):241-7. PubMed ID: 12647553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome.
    Chiba K; Sugiyama A; Hagiwara T; Takahashi S; Takasuna K; Hashimoto K
    Eur J Pharmacol; 2004 Feb; 486(2):189-200. PubMed ID: 14975708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline values and sotalol-induced changes of ventricular repolarization duration, heterogeneity, and instability in patients with a history of drug-induced torsades de pointes.
    Couderc JP; Kaab S; Hinterseer M; McNitt S; Xia X; Fossa A; Beckmann BM; Polonsky S; Zareba W
    J Clin Pharmacol; 2009 Jan; 49(1):6-16. PubMed ID: 18957528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Torsade de pointes probably induced by sparfloxacin.
    Kakar A; Byotra SP
    J Assoc Physicians India; 2002 Aug; 50():1077-8. PubMed ID: 12421038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications.
    Briasoulis A; Agarwal V; Pierce WJ
    Cardiology; 2011; 120(2):103-10. PubMed ID: 22156660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythromycin induced torsades de pointes.
    Wong CB; Windle J
    Nebr Med J; 1995 Sep; 80(9):285-6. PubMed ID: 7566254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Side effects, unwanted drug interactions and the problem of cardiotoxicity].
    WoroĊ„ J; Trabka-Janik E; Kostka-Trabka E
    Przegl Lek; 2003; 60(4):196-8. PubMed ID: 14569882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Torsades de pointes associated with astemizole (Hismanal) therapy.
    Goss JE; Ramo BW; Blake K
    Arch Intern Med; 1993 Dec; 153(23):2705. PubMed ID: 8250668
    [No Abstract]   [Full Text] [Related]  

  • 19. Sotalol-induced torsades de pointes in patients with renal failure.
    Dancey D; Wulffhart Z; McEwan P
    Can J Cardiol; 1997 Jan; 13(1):55-8. PubMed ID: 9039065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Torsades de pointes associated with acquired long QT syndrome: observation of 7 cases.
    Takahashi N; Ito M; Inoue T; Koumatsu K; Takeshita Y; Tsumabuki S; Tamura M; Inoue K; Maeda T; Saikawa T
    J Cardiol; 1993; 23(1):99-106. PubMed ID: 8164140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.